IL33 and atopic eczema: Several neutralizing antibodies against IL-33 are currently in early phases of clinical development as therapeutic approaches for asthma, COPD (chronic obstructive pulmonary disease), atopic dermatitis, or chronic rhinosinusitis with nasal polyps (Table 2).